REIN THERAPEUTICS INC (RNTX)

NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations

www.aileronrx.com

∆ Upcoming Events

Jun 30, 2025, 5:00:00 AM UTC

Phase 2 Clinical Trial Initiation of LTI-03

Rein Therapeutics plans to initiate a Phase 2 clinical trial for LTI-03 targeting idiopathic pulmonary fibrosis in the first half of 2025, aiming to address significant unmet medical needs.

clinical readout

Jun 30, 2026, 5:00:00 AM UTC

RENEW Phase 2 Trial Topline Interim Data

Rein Therapeutics is set to release topline interim data from its RENEW Phase 2 trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF) on June 30, 2026. This trial aims to assess the safety, tolerability, and efficacy of LTI-03, marking a significant milestone for the company in its efforts to address unmet medical needs in pulmonary diseases.

clinical readout